Evaluating the Association between CCR5delta32 Polymorphism (rs333) and the Risk of Breast Cancer in a Cohort of Iranian Population

Amir Tajbakhsh; Zahra Farjami; Abolfazl Nesaei-Bajestani; Fahimeh Afzaljavan; Mahdi Rivandi; Atefeh Moezzi; Soheila Abedini; Mahla Asghari; Mohammad Mahdi Kooshyar; Fatemeh Homaei Shandiz; Alireza Pasdar

doi:10.18502/ijph.v50i3.5604

Evaluating the Association between CCR5delta32 Polymorphism (rs333) and the Risk of Breast Cancer in a Cohort of Iranian Population

Iran J Public Health. 2021 Mar;50(3):583-591. doi: 10.18502/ijph.v50i3.5604.

Authors

Amir Tajbakhsh^{1

2

3}, Zahra Farjami^{2

3}, Abolfazl Nesaei-Bajestani⁴, Fahimeh Afzaljavan², Mahdi Rivandi², Atefeh Moezzi^{2

3}, Soheila Abedini², Mahla Asghari², Mohammad Mahdi Kooshyar⁵, Fatemeh Homaei Shandiz⁶, Alireza Pasdar^{2

7

8}

Affiliations

¹ Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
² Department of Medical Genetics & Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mash-had, Iran.
³ Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ Department of Basic Sciences, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran.
⁵ Department of Hematology-Oncology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Cancer Research Center, Mashhad University of Medical University, Mashhad, Iran.
⁷ Division of Applied Medicine, Faculty of Medicine, University of Aberdeen, Foresterhill, Aberdeen, UK.
⁸ Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Background: CC chemokine receptor 5 (CCR5) is introduced as an immune response modulator. The activity of CCR5 influences breast tumour development in a p53-dependent manner. This study aimed to investigate the frequency of CCR5delta32 and its association with the risk of breast cancer in 1038 blood samples in North East of Iran.

Methods: In this case-control study, we genotyped 570 control samples and 468 breast cancer patients by a gel electrophoresis-based gap-polymerase chain reaction (gap-PCR) method Mashhad, Iran. The data were analyzed using the SPSS software.

Results: Of 570 controls included, 542 (95.09%) had CCR5delta32 ^{wild/wild (W/W)} genotype, 28 samples (4.91%) had CCR5delta32 ^{wild/deletion (W/D)} genotype and none of them were CCR5delta32 ^{deletion/deletion (D/D)} genotype (0%). While 428 samples of patients (91.45%) had CCR5delta32 ^W/W genotype, 40 samples (8.55%) had CCR5delta32 ^W/D and CCR5delta32 ^D/D homozygous was nil (0%) amongst cases. All samples were in the Hardy-Weinberg equilibrium (P>0.05). According to the allele frequency, D allele, as a risky allele, in the cases was more than the control samples (0.0427 vs 0.0245, respectively) (P=0.0206). Hence, W/D genotype may confer a risk effect (OR=1.77, CI: 1.09-2.90; P=0.0206) compared with WW genotype between case and control groups.

Conclusion: There is a statistically significant association between CCR5W/D and breast cancer risk. CCR5 may be regarded as a target for the prevention of breast cancer in certain conditions such as interaction with p53 variants, which remains to be further investigated.

Keywords: Breast carcinoma; CCR5delta32; Immunogenetics; Metastasis; p53 pathway.